Importantly, HER2– tumours that are very sensitive to oestrogen are usually considered to be relatively low risk, yet these were the tumours that showed an increase in recurrence after five years, which coincided with the cessation of adjuvant hormonal therapy. This evidence concerns the gene ERBB2 and neoplasm.